Seizure-European Journal of Epilepsy最新文献

{"title":"Candidates for focal cortex stimulation in the outpatient population of an epilepsy reference center","authors":"Martin Hirsch ,&nbsp;Susana Palao ,&nbsp;Birgitta Metternich ,&nbsp;Yulia Novitskaya ,&nbsp;Andreas Schulze-Bonhage","doi":"10.1016/j.seizure.2025.05.023","DOIUrl":"10.1016/j.seizure.2025.05.023","url":null,"abstract":"<div><h3>Background</h3><div>Focal Cortex Stimulation (FCS) is a novel treatment for epilepsy. The patient population that may benefit from FCS has not been identified yet. This study uses data from a clinical trial screening at a tertiary epilepsy center's outpatient clinic to estimate the potential for FCS application</div></div><div><h3>Objective</h3><div>To determine the proportion of people with epilepsy (PWE) who could benefit from FCS considering focus localization and extent</div></div><div><h3>Methods</h3><div>All adult patients at the Freiburg epilepsy center outpatient clinic between October 1, 2019 and January 31, 2020, were screened for FCS eligibility. Suitable candidates needed to have 1) one predominant epileptic focus, 2) focus localization at the dorsolateral convexity, and 3) estimated focus size &lt; 5 cm in diameter</div></div><div><h3>Results</h3><div>Epilepsy was confirmed in 562 of 604 patients. FCS was precluded in 205 patients due to specific epilepsy syndromes (e.g., genetic generalized epilepsies, mesiotemporal, unclassified). Patients with malignant tumors (25) or lesions outside the dorsolateral convexity (21) were excluded. In 16 of 41 multilesional patients and 18 of 35 nonlesional patients, a predominant focus was identified via EEG/semiology. In 40 of 127 patients with a neocortical single lesion, the lesion was deemed too extensive for FCS. Overall, 121 patients (21.5 % of all PWE, 26.5 % of focal epilepsy patients) were suitable for FCS, 56 of whom were drug-resistant</div></div><div><h3>Conclusions</h3><div>A significant proportion of PWE at a tertiary epilepsy center have a neocortical focus at the dorsolateral convexity, making them potential candidates for FCS. Given its efficacy and tolerability, FCS is a promising treatment for a major subgroup of patients with drug-resistant focal epilepsy</div></div>","PeriodicalId":49552,"journal":{"name":"Seizure-European Journal of Epilepsy","volume":"131 ","pages":"Pages 11-15"},"PeriodicalIF":2.7,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144205531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiac arrhythmias in patients with focal and generalised epilepsy undergoing ambulatory electroencephalographic and electrocardiographic monitoring","authors":"Francis J Ha ,&nbsp;Shuyu Wang ,&nbsp;Duron Prinsloo ,&nbsp;Vanessa Di Tano ,&nbsp;Tai Ermongkonchai ,&nbsp;Ewan S Nurse ,&nbsp;Mark J Cook","doi":"10.1016/j.seizure.2025.05.022","DOIUrl":"10.1016/j.seizure.2025.05.022","url":null,"abstract":"<div><h3>Background</h3><div>Epilepsy may be associated with cardiac arrhythmias. The specific incidence and types of cardiac arrhythmias in different forms of epilepsy is not clearly defined.</div></div><div><h3>Methods</h3><div>We evaluated patients aged 16 years or older referred for continuous home-based ambulatory video–electroencephalographic(EEG)–electrocardiographic(ECG) monitoring (AVEEM) across 24 sites in Australia between 2020 and 2023. Data collected included baseline demographics, type of epilepsy according to EEG findings, and cardiac arrhythmias (ictal and non-ictal) during monitoring. Logistic regression was used to evaluate association between potential risk factors and cardiac arrhythmias.</div></div><div><h3>Results</h3><div>A total of 866 patients with focal epilepsy and 274 with generalised epilepsy were identified who underwent AVEEM. Patients with generalised epilepsy were younger (median age 24 years versus 43 years) and more likely female (69 % versus 55 %) compared with focal epilepsy. Patients with focal epilepsy had more cardiac arrhythmias (279/866; 32 %) compared with generalised epilepsy (40/274; 15 %; <em>p</em> = 0.04). In patients with focal epilepsy, there were more cardiac arrhythmias observed in temporal lobe epilepsy (238/688; 35 %) compared with extra-temporal lobe focal epilepsy (16/82; 20 %; <em>p</em> = 0.006). However, on multivariable analysis only increased age (<em>p</em> &lt; 0.001) remained a significant predictor of increased cardiac arrhythmias. Right or left sided origin of focal epilepsy was not associated with a difference in cardiac arrhythmias (<em>p</em> = 0.63).</div></div><div><h3>Conclusions</h3><div>Patients with focal epilepsy had more cardiac arrhythmias compared with generalised epilepsy that was explained by increased age. This study demonstrates feasibility of longer term ambulatory EEG-ECG monitoring in the outpatient setting for real-world assessment of cardiac arrhythmias in patients with epilepsy.</div></div>","PeriodicalId":49552,"journal":{"name":"Seizure-European Journal of Epilepsy","volume":"131 ","pages":"Pages 90-94"},"PeriodicalIF":2.7,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144271057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genotype and phenotype correlation in epilepsy patients with SMARCA2 variants","authors":"Ying Yang ,&nbsp;Tianyi Xin ,&nbsp;Dan Sun ,&nbsp;Xiaoli Zhang ,&nbsp;Yan Sun ,&nbsp;Jiaxin Zhuang ,&nbsp;Hao Chen ,&nbsp;Xiujing Wang ,&nbsp;Bing Han ,&nbsp;Yuehua Zhang","doi":"10.1016/j.seizure.2025.05.019","DOIUrl":"10.1016/j.seizure.2025.05.019","url":null,"abstract":"<div><h3>Aim</h3><div>This study aimed to determine the genotype and phenotype correlations for the <em>SMARCA2</em> gene in epilepsy patients.</div></div><div><h3>Method</h3><div>We analysed the genotype-phenotype correlations of 24 patients in our cohort and evaluated 46 epilepsy patients from published studies.</div></div><div><h3>Results</h3><div>In our cohort, 21 variants were identified in 24 patients. Two variants, p.P883L and p.G853R, were identified in two patients. 21 variants were de novo, and 17 were novel. Seizure onset ages ranged from 1 day to 75 months (median age: 15 months). The predominant seizure type was focal seizures (60.9 %). Five patients were diagnosed with developmental epileptic encephalopathy. In our cohort, 52.8 % of epilepsy patients had dental diseases, including widely spaced teeth, fused teeth, and hypodontia. Collectively, in the published studies and our cohort of patients with <em>SMARCA2</em> variants, 77.3 % (51/66) of the variants were located in the SNF2-ATPase domain. Seizures were controlled in 45.8 % (11/24) of the patients in our cohort by valproate or levetiracetam.</div></div><div><h3>Interpretation</h3><div>The variations in <em>SMARCA2</em> in epilepsy patients were predominantly located in the SNF2-ATPase domain. The clinical features of <em>SMARCA2</em>-related epilepsy include seizure onset in infancy, and focal seizures. Dental abnormalities are among the significant phenotypes observed in patients with <em>SMARCA2</em> variants.</div></div>","PeriodicalId":49552,"journal":{"name":"Seizure-European Journal of Epilepsy","volume":"131 ","pages":"Pages 73-83"},"PeriodicalIF":2.7,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144271037","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness and safety of cenobamate in Lennox-Gastaut syndrome: A multicenter real-world study in Spain","authors":"Maria José Aguilar-Amat Prior ,&nbsp;Pablo Alonso Singer ,&nbsp;Javier Oliva Navarro ,&nbsp;Laura Olivie Garcia ,&nbsp;Maria Machio Castello ,&nbsp;Álvaro Beltran-Corbellini ,&nbsp;Álvaro Sánchez-Larsen ,&nbsp;Beatriz Parejo-Carbonell ,&nbsp;Maria de Toledo-Heras ,&nbsp;Alba Vieira Campos ,&nbsp;Esther Gonzalez-Villar ,&nbsp;Blanca Mercedes-Alvarez ,&nbsp;Juan Manuel Escobar-Montalvo","doi":"10.1016/j.seizure.2025.05.011","DOIUrl":"10.1016/j.seizure.2025.05.011","url":null,"abstract":"<div><h3>Objective</h3><div>Lennox-Gastaut syndrome (LGS) is a rare treatment-resistant epilepsy classed as developmental and epileptic encephalopathy (DEE). In this study we investigated the effectiveness and safety of cenobamate (CNB) as adjunctive therapy in adults with LGS under real-world conditions.</div></div><div><h3>Methods</h3><div>We conducted a retrospective analysis of clinical data collected from patients diagnosed with LGS who were prescribed CNB in 8 different sites. Data was sourced from patient clinical records. Effectiveness was evaluated by seizure type (total seizures, focal onset seizures, generalized tonic-clonic seizures [GTCS], drop seizures and atypical absence) and included ≥50 %, ≥75 %, ≥90 % responder rate and seizure freedom rate at 3, 6 and 12month visits. Changes in the number of co-antiseizure medication (co-ASM) were also analyzed. Safety/tolerability was monitored by documenting the incidence of adverse events (AE) and AEs leading to discontinuation.</div></div><div><h3>Results</h3><div>18 patients with LGS were included in the analysis (34.4 % women, mean age 25.2 years, and median number of seizures per month 195 (IQR: 12–1416)). The median of number of prior ASMs and concomitant ASMs were 12 (IQR: 8–16) and 3 (IQR: 2–6) respectively. Median CNB dosages/day was 200 mg (IQR: 50–350) at 3, 6 and 12 months. At 3, 6, and 12 months, 94.4 %, 94.4 % and 83.3 % of participants were retained on CNB treatment, respectively. At the last available visit, the seizure freedom rate was 12.5 %, ≥50 %, ≥75 %, ≥90 % responder rates were 46.2 %, 23.1 %, and 0 %, respectively. The number of co-ASMs was reduced in 36 % of patients. The percentage of patients with AEs and AEs leading to discontinuation was 0 %. The most frequent AEs were somnolence and bradypsychia or dizziness.</div></div><div><h3>Conclusion</h3><div>In this study, CNB demonstrated high effectiveness and good tolerability in patients with LGS when administered in adjuvancy in real-world practice after the failure of multiple ASMs. AEs were frequent but mostly mild-to-moderate.</div></div>","PeriodicalId":49552,"journal":{"name":"Seizure-European Journal of Epilepsy","volume":"131 ","pages":"Pages 84-89"},"PeriodicalIF":2.7,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144271056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treating seizures in SYN1-related epilepsy: a systematic review","authors":"Elisabeth Van Boxstael ,&nbsp;Eric Vigneul ,&nbsp;Susana Ferrao Santos","doi":"10.1016/j.seizure.2025.05.017","DOIUrl":"10.1016/j.seizure.2025.05.017","url":null,"abstract":"<div><div>Introduction: <em>Synapsin1</em>-related epilepsy is a rare entity, in which patients typically present reflex seizures, provoked by contact with water. Moreover, patients carrying a pathogenic variant of the synapsin 1 gene (<em>SYN1</em>) can present developmental delay, behavior disorders, and other types of seizures. While <em>SYN1</em>-related epilepsy becomes better characterized, there is still no consensus on the appropriate antiseizure medication (ASM) to use.</div><div>Materials and methods: To compare ASMs efficacies in this particular syndrome, we performed a systematic literature review according to the PRISMA guidelines by using PubMed and Embase databases. All the studies reflecting the seizure outcome associated with the treatment of <em>SYN1</em>-related epilepsy were included in the present review, except those that were not written in English or were in the forms of poster, commentary, or conference abstract.</div><div>Results: Eight studies and a total of 52 patients with well-documented treatment were retrieved from the literature. The most frequently used ASMs were valproic acid (VPA) (58 %), lamotrigine (LTG) (35 %) and carbamazepine (CBZ) (35 %). Regarding seizure-free patients, the most effective ASMs were lacosamide (LCM) (50 %), oxcarbazepine (OXC) (44 %) and CBZ (38 %). When considering seizure-freedom or significant (≥ 50 %) seizure reduction, the best treatment is LTG (63 %), followed by LCM (50 %) and CBZ (50 %). LTG, CBZ, OXC and LCM seem to be associated with a more favorable seizure outcome compared to levetiracetam (LEV) or VPA, with a statistically significant difference in terms of seizure reduction (<em>p</em> = 0.028) and seizure freedom for patients carrying a non-truncating variant (<em>p</em> = 0.047).</div><div>Conclusion: Based on our systematic literature review, patients with <em>SYN1</em>-related epilepsy show better seizure frequency reduction when treated with LCM, LTG, CBZ, or OXC, compared to VPA and LEV, despite VPA being the most prescribed anti-seizure medication for this syndrome. Hence, sodium channel blockers appear to represent the best therapeutic option for these patients.</div></div>","PeriodicalId":49552,"journal":{"name":"Seizure-European Journal of Epilepsy","volume":"131 ","pages":"Pages 105-112"},"PeriodicalIF":2.7,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144307909","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cenobamate use in pregnancy: A case report","authors":"Tiara Paul ,&nbsp;Maromi Nei","doi":"10.1016/j.seizure.2025.05.016","DOIUrl":"10.1016/j.seizure.2025.05.016","url":null,"abstract":"","PeriodicalId":49552,"journal":{"name":"Seizure-European Journal of Epilepsy","volume":"131 ","pages":"Pages 26-28"},"PeriodicalIF":2.7,"publicationDate":"2025-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144212760","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to \"Efficacy and safety of Cenobamate: a multicenter, retrospective evaluation of real-world clinical practice\" [Seizure: European Journal of Epilepsy 130 (2025) 25-31].","authors":"Magdalena Bosak, Hanna Podraza, Dorota Włoch-Kopeć, Andrzej Rysz, Kamil Wężyk, Katarzyna Grabska-Radzikowska, Piotr Sobolewski, Tomasz Siwek, Iwona Kurkowska-Jastrzębska, Monika Służewska-Niedźwiedź, Katarzyna Sulima, Lech Kipiński, Lidia Kiryła, Katarzyna Stopińska, Elżbieta Płonka-Półtorak, Justyna Tabaka-Pradela, Magdalena Konopko, Agnieszka Meller, Monika Chorąży, Maja Kopytek-Beuzen, Dorota Dzianott-Pabijan, Małgorzata Klimas, Krzysztof Nicpoń, Łukasz Jasek, Karolina Machowska-Sempruch, Katarzyna Fuksa, Katarzyna Zawiślak-Fornagiel","doi":"10.1016/j.seizure.2025.05.008","DOIUrl":"https://doi.org/10.1016/j.seizure.2025.05.008","url":null,"abstract":"","PeriodicalId":49552,"journal":{"name":"Seizure-European Journal of Epilepsy","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144144234","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of induced burst suppression on outcomes in patients with POLG-related status epilepticus.","authors":"Kristin N Varhaug, Eivind Aanestad, Gunhild Holmaas, Yvonne Myrtvedt Wollertsen, Siren Berland, Gyri Veiby, Tom Eichele, Marte-Helene Bjørk, Shamima Rahman, Omar Hikmat","doi":"10.1016/j.seizure.2025.05.004","DOIUrl":"https://doi.org/10.1016/j.seizure.2025.05.004","url":null,"abstract":"<p><strong>Purpose: </strong>Management of status epilepticus in patients with POLG-related disease is challenging as many patients with POLG-related status epilepticus progress to refractory or super-refractory status epilepticus, often with fatal outcome. We aimed to study the impact of induced burst suppression on seizure control and survival in patients with POLG-related refractory status epilepticus, describe the extent of anaesthetic agents needed to induce burst suppression, and the potential side-effects of long-term anaesthesia.</p><p><strong>Methods: </strong>A total of 15 trials of induced burst suppression in six patients with genetically confirmed POLG-related disease were analysed. Time points of status epilepticus start, intubation, induction of burst suppression, extubation and death, together with the total length of burst suppression, and details on anaesthetic agents and anti-seizure medications used during burst suppression induction were systematically collected.</p><p><strong>Results: </strong>Rapid induction of burst suppression (< 24 h) from the onset of status epilepticus showed a mean survival time of 171.3 days, versus 140.7 days when burst suppression was induced after 24 h. Patients with burst suppression lasting <48 h had a mean survival of 238 days, whereas those with burst suppression lasting >48 h had a mean survival time of 161.7 days. The induction of burst suppression required multiple anaesthetic agents. We did not find any evidence of propofol-infusion syndrome.</p><p><strong>Conclusion: </strong>Treatment of POLG-related status epilepticus is extremely challenging and has a major impact on survival. The role of early and prolonged burst suppression in treatment of refractory status epilepticus in patients with POLG-related disease should be further studied.</p>","PeriodicalId":49552,"journal":{"name":"Seizure-European Journal of Epilepsy","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144217375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Experiences of individuals with functional/dissociative seizures with healthcare professionals: A systematic review and thematic synthesis","authors":"Lucy Eaves ,&nbsp;Jane Simpson ,&nbsp;Markus Reuber","doi":"10.1016/j.seizure.2025.04.020","DOIUrl":"10.1016/j.seizure.2025.04.020","url":null,"abstract":"<div><h3>Objective</h3><div>Research suggests people with functional/dissociative seizures (pwFDS) often experience challenging encounters with healthcare professionals (HCPs). PwFDS report communication problems, difficult relationships with HCPs and sub-standard care. However, no previous reviews have explored this issue from the perspective of pwFDS. Therefore, this systematic review aimed to explore pwFDS’ experiences of their encounters with HCPs.</div></div><div><h3>Methods</h3><div>Four databases (Scopus, PsycINFO, CINAHL and MEDLINE) were systematically searched for peer-reviewed qualitative studies in February 2024. Twenty studies published 2004–2023 with 270 pwFDS were included and analysed using thematic synthesis. The Critical Appraisal Skills Programme checklist for qualitative research was utilised to appraise the quality of included studies.</div></div><div><h3>Results</h3><div>The findings highlight a number of difficulties which pwFDS face in their encounters with HCPs. Three superordinate themes with five subthemes were developed: ‘clinician uncertainty feeds patient uncertainty’, ‘not fitting into the model of medical illness’, ‘stigma fuelling negative experiences with HCPs’. Positive encounters were mentioned but these were reported in the minority of instances.</div></div><div><h3>Conclusions</h3><div>Findings highlight the difficult experiences pwFDS face in their encounters with HCPs. PwFDS experience uncertainty about their condition due to poor knowledge and stigmatising beliefs about FDS. Difficult encounters with HCPs are frequently experienced, which may lead pwFDS to avoid accessing medical support.</div></div>","PeriodicalId":49552,"journal":{"name":"Seizure-European Journal of Epilepsy","volume":"131 ","pages":"Pages 35-49"},"PeriodicalIF":2.7,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144231129","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Features of developmental coordination disorder and sleep difficulties in young adolescents with epilepsy: A case-controlled study","authors":"C Meades ,&nbsp;J Idowu ,&nbsp;JH Cross ,&nbsp;S Chan ,&nbsp;A Muggeridge ,&nbsp;M Lakhanpaul ,&nbsp;K Robinson ,&nbsp;LB Sherar ,&nbsp;N Pearson ,&nbsp;C Reilly","doi":"10.1016/j.seizure.2025.05.015","DOIUrl":"10.1016/j.seizure.2025.05.015","url":null,"abstract":"<div><h3>Objective</h3><div>The primary aim was to compare the prevalence of difficulties with motor coordination and sleep in young adolescents with epilepsy (11–16 years) (<em>n</em> = 60) and a healthy control group (<em>n</em> = 49). The secondary aim was to explore factors associated with sleep and motor coordination in the epilepsy group.</div></div><div><h3>Methods</h3><div>Children with ‘active’ epilepsy, controls, and caregivers completed a measure of sleep (Insomnia Severity Index and Child Sleep Habits Questionnaire respectively). Caregivers also completed a measure of child motor coordination – Developmental Coordination Disorder (DCD) - Questionnaire (DCD-Q). Comparisons between the epilepsy and control group were undertaken using chi-square analysis and independent <em>t</em>-tests. Factors associated with sleep and motor coordination in children with epilepsy were explored using linear regression analysis. Alpha level was <em>p</em> &lt; 0.05 and effect sizes are reported using Cohen’s d.</div></div><div><h3>Results</h3><div>The epilepsy and control group were matched on age, gender, and socioeconomic status. Children with epilepsy were significantly more likely to be at-risk for DCD than controls (45 % vs 12 %; <em>p</em> &lt; 0.001). Children with epilepsy had more sleep difficulties than controls on self (<em>p</em> = 0.003; <em>d</em> = 0.581) and caregiver reports (<em>p</em> &lt; 0.001; <em>d</em> = 1.230). Linear regression showed that the factors associated with DCD-Q scores on multivariable analysis were: age of seizure onset (<em>p</em> &lt; 0.001), child mental health (<em>p</em> = 0.013), child sleep problems (<em>p</em> = 0.034), and epilepsy medication (<em>p</em> = 0.030). Children with a younger age of epilepsy onset, with more self-reported mental health problems, on polypharmacy and experiencing more sleep problems had increased DCD-Q scores. Regarding child-reported sleep, children with more sleep difficulties had a significantly greater degree of reported DCD features (<em>p</em> &lt; 0.001).</div></div><div><h3>Significance</h3><div>Young adolescents with epilepsy should be screened for sleep and motor coordination difficulties. Future research should focus on interventions to support children with epilepsy to reduce the impact of these difficulties on everyday functioning.</div></div>","PeriodicalId":49552,"journal":{"name":"Seizure-European Journal of Epilepsy","volume":"131 ","pages":"Pages 5-10"},"PeriodicalIF":2.7,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144195565","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}